These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35354411)

  • 1. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
    Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
    Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
    Tomaszewska-Kiecana M; Ullmann M; Petit-Frere C; Monnet J; Dagres C; Illes A
    Expert Rev Clin Immunol; 2023 Apr; 19(4):439-446. PubMed ID: 36715299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
    Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
    Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study.
    Zubrzycka-Sienkiewicz A; Klama K; Ullmann M; Petit-Frere C; Baker P; Monnet J; Illes A
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38316489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults.
    Haranaka M; Tanaka T; Kim S; Bae Y; Jeon D; Choi E; Cha J; Lee S; Ogama Y
    Immunotherapy; 2023 Feb; 15(3):149-161. PubMed ID: 36748363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
    Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
    Expert Opin Biol Ther; 2024 Jul; 24(7):681-689. PubMed ID: 38905143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
    Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
    Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
    Bellon A; Wang J; Skerjanec A; Velinova M; Dickerson D; Sabet A; Ngo L; O'Reilly T; Tomek C; Schussler S; Schier-Mumzhiu S; Gattu S; Koch SD; Schelcher C; Dobreva M; Boldea A; Nakov R; Otto GP
    Br J Clin Pharmacol; 2020 Jun; 86(6):1139-1149. PubMed ID: 32022282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
    Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
    BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
    Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
    Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
    Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
    Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
    Wessels H; von Richter O; Velinova M; Höfler J; Chamberlain P; Kromminga A; Lehnick D; Roth K
    Expert Opin Biol Ther; 2023; 23(12):1287-1297. PubMed ID: 38044885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
    Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
    Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.